HomeAI · summaries
Storia in 3 fonti
Novo Nordisk ends Hims & Hers tie-up over copycat Wegovy drugs
Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
ft.com
Novo hunts for ‘maximum potential’ from obesity drug CagriSema
Danish group lost €90bn in market capitalisation in December after preliminary results showed it missed its target
- ·
cnbc.com
Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%
Novo Nordisk said Hims & Hers has "failed to adhere to the law which prohibits mass sales of compounded drugs" under the "false guise" of personalization.
